Generic PENTOBARBITAL INN entry, pharmaceutical patent and freedom to operate

Sponsor	Phase
Sohag University	Phase 2/Phase 3
Assiut University	N/A
Children's Hospital Medical Center, Cincinnati	Phase 1

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Rising	NEMBUTAL SODIUM	pentobarbital sodium	INJECTABLE;INJECTION	083246-001	Approved Prior to Jan 1, 1982	AP	RX	Yes	Yes	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Vitarine	PENTOBARBITAL SODIUM	pentobarbital sodium	TABLET;ORAL	083285-001	Approved Prior to Jan 1, 1982		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Watson Labs	SODIUM PENTOBARBITAL	pentobarbital sodium	CAPSULE;ORAL	085791-001	Approved Prior to Jan 1, 1982		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Last updated: September 4, 2026

Pentobarbital is a mature, off-patent barbiturate with limited public financial disclosure. Its commercial value is concentrated in injectable hospital products, veterinary euthanasia, controlled-access institutional supply, and specialized end-of-life or execution markets. Revenue is driven more by manufacturing capacity, controlled-substance regulation, procurement restrictions, and supply interruptions than by clinical innovation.

The market has no meaningful biologic, biosimilar, or novel-brand growth component. U.S. exclusivity has expired, current patent barriers are minimal, and generic entry is legally possible. Commercial volatility remains high because the number of qualified suppliers is limited and buyers often cannot substitute freely across formulations or routes of administration.

What is pentobarbital and where is it used?

Pentobarbital is a short- to intermediate-acting barbiturate marketed primarily as pentobarbital sodium. Its pharmacologic effects include central nervous system depression, sedation, hypnosis, anesthesia, and respiratory suppression at higher doses.

Segment	Principal use	Commercial characteristics
Human injectable medicine	Sedation, seizure control, induction of anesthesia, emergency use	Small hospital market; procurement depends on injectable availability
Veterinary medicine	Euthanasia and anesthesia	Important recurring demand; concentrated among veterinary suppliers
Laboratory and research use	Animal anesthesia and controlled experimental applications	Low-volume, specialized demand
Execution protocols	State-administered lethal injection protocols	Highly restricted, politically sensitive, irregular demand
End-of-life use	Certain jurisdictions and institutional settings	Legally fragmented and limited by prescribing rules

The FDA-approved U.S. labeling for Nembutal Sodium Injection identifies indications including sedative, hypnotic, and preanesthetic use, while warning about respiratory depression, dependence, and controlled-substance risks (FDA, 2019). Pentobarbital is not a modern first-line therapy for most routine insomnia, anxiety, or seizure indications because safer alternatives are available.

How large is the pentobarbital market?

No public company reports pentobarbital revenue as a separate operating line. The market is too small and fragmented for reliable standalone global revenue estimates from public filings. Manufacturer disclosures usually combine pentobarbital with broader injectable, hospital, veterinary, or specialty-pharmaceutical portfolios.

A practical market assessment is:

Human pharmaceutical demand is niche and declining in clinical importance.
Veterinary demand is recurring but exposed to supplier and distributor concentration.
Execution-related demand is irregular and does not create a stable commercial base.
Research demand is small relative to medical and veterinary consumption.
Pricing can rise sharply during shortages because buyers have limited immediate substitutes for injectable pentobarbital.

The commercial value of pentobarbital therefore depends on volume stability and supply reliability rather than patent-protected pricing. A manufacturer with an approved injectable product, validated controlled-substance handling, and established hospital or veterinary distribution can earn attractive unit margins despite a small addressable market. Those margins can disappear when a competitor restores supply or when a regulator imposes procurement restrictions.

What is the financial trajectory for pentobarbital?

Pentobarbital has a mature-to-declining long-term volume trajectory in human medicine. The product’s financial profile is more accurately described as a constrained generic market than as a growth pharmaceutical market.

Revenue drivers

The main revenue drivers are:

Injectable product availability.
Hospital purchasing contracts.
Veterinary clinic and distributor demand.
Controlled-substance quota allocation.
Manufacturing-site reliability.
Product concentration and presentation.
State or institutional procurement rules.
Temporary shortages affecting substitute products.

Revenue constraints

The principal constraints are:

Expired composition-of-matter and formulation protection.
Substitution by newer anesthetics and anticonvulsants.
Low prescription volume in routine human care.
Regulatory controls under the Controlled Substances Act.
Reputational and political exposure associated with executions.
Limited willingness by manufacturers to expand capacity for a narrow market.
Difficulty obtaining active pharmaceutical ingredient and qualified sterile manufacturing capacity.

A reasonable financial model would treat pentobarbital as a low-growth product with episodic price expansion. Revenue may rise during shortages without corresponding increases in underlying demand. That increase is vulnerable to normalization once another supplier qualifies, a back order clears, or buyers move to alternative products.

When does pentobarbital lose exclusivity?

Pentobarbital lost meaningful U.S. market exclusivity decades ago. The active ingredient was introduced in the early 20th century, and the principal commercial products are generic or legacy branded formulations. No current U.S. patent estate is known to provide commercially meaningful exclusivity for ordinary pentobarbital sodium injection.

Exclusivity category	Current position
Composition-of-matter patent	Expired
Original product patent	Expired
Routine injectable formulation patent	No meaningful active barrier identified
New chemical entity exclusivity	Expired
Pediatric exclusivity	No current relevance identified
Orphan-drug exclusivity	Not a principal market protection
Biosimilar exclusivity	Not applicable
Generic approval pathway	Available, subject to FDA requirements

The absence of patent protection does not mean that every potential competitor can launch immediately. A supplier still needs an approved application, compliant sterile manufacturing, controlled-substance authorization, validated supply, and sufficient commercial distribution.

What patents protect pentobarbital products?

No current patent category appears to protect the basic pentobarbital molecule in the United States. Potentially relevant intellectual-property rights would be limited to narrow claims involving:

A particular concentration.
A specific injectable vehicle or stabilizer.
A specialized container or delivery system.
A manufacturing process.
A combination with another active ingredient.
A new method of use.

These rights would need to be assessed claim by claim. They would not ordinarily recreate broad exclusivity for standard pentobarbital sodium injection.

The patent position differs from regulatory protection. A manufacturer may hold trade secrets covering sterile processing, impurity control, filling, or supply qualification even when the product has no enforceable patent barrier. Those process capabilities can delay competitor entry, but they are manufacturing advantages rather than market exclusivity.

What is the FDA regulatory status and Orange Book position?

Pentobarbital is regulated as an approved prescription drug when marketed under an FDA-approved application. Nembutal Sodium Injection has historically been listed as a prescription injectable product, while generic pentobarbital sodium products have entered through abbreviated or legacy approval pathways depending on the product and sponsor.

The FDA Orange Book identifies approved drug applications and patent or exclusivity information. For a mature product such as pentobarbital, the key commercial question is not whether the molecule has historical approval, but whether an active sponsor is maintaining a currently marketed, commercially available presentation.

FDA issue	Market impact
Approved injectable application	Allows lawful commercial marketing for labeled uses
Discontinued application	Can reduce practical supply even when the product remains legally approved
Drug shortage listing	Can increase prices and purchasing urgency
Controlled-substance requirements	Restrict manufacturing, distribution, inventory, and prescribing
Manufacturing compliance	Creates a non-patent barrier to entry
Orange Book patent listing	No broad current exclusivity expected for the base product

FDA approval does not guarantee continuous availability. Products can remain legally recognized while becoming commercially unavailable because of manufacturing, business, or supply-chain decisions.

Are there paragraph IV challenges involving pentobarbital?

Paragraph IV litigation is not a central current issue for pentobarbital. The principal U.S. patents protecting the original drug have expired, leaving little commercial incentive for patent holders to litigate routine generic entry.

A generic applicant would generally face more practical risk from:

FDA deficiencies.
Sterile manufacturing validation.
Controlled-substance registration.
Active-ingredient sourcing.
Bioequivalence or product-specific approval requirements.
Distribution restrictions.
Commercial supply commitments.

The lack of significant paragraph IV activity supports the conclusion that pentobarbital competition is governed by regulatory execution and manufacturing capacity rather than patent litigation.

Which companies compete in the pentobarbital market?

Competition varies by country and product presentation. Historically associated manufacturers and suppliers have included Lundbeck for Nembutal, Akorn for certain injectable products, and veterinary pharmaceutical suppliers serving animal-health channels. Product ownership, marketing status, and availability can change after divestitures, discontinuations, recalls, or manufacturing transfers.

The market has three competitive layers:

Human pharmaceutical manufacturers

These companies compete for hospital and institutional procurement. The relevant assets are sterile injectable capacity, FDA compliance, controlled-substance handling, and continuity of supply.

Veterinary manufacturers and distributors

Veterinary demand is commercially important because euthanasia products are used repeatedly across clinics and animal-health systems. Veterinary products may have separate labels, concentrations, packaging, and distribution channels.

Institutional and restricted-use suppliers

Execution and other controlled institutional uses can involve direct procurement, special contracts, import restrictions, and confidential purchasing arrangements. This segment does not provide predictable volume for ordinary pharmaceutical forecasting.

What formulation patents and manufacturing barriers matter?

Pentobarbital is available primarily as an injectable sodium salt, with product-specific differences in concentration, excipients, container, and administration instructions. Those differences can affect substitution even when the active ingredient is identical.

Manufacturing barriers include:

Sterile injectable production.
Control of particulate and microbial contamination.
Stability and impurity testing.
Controlled-substance inventory systems.
DEA registration and quota management.
Qualified pentobarbital API supply.
Specialized packaging and labeling.
Hospital and veterinary distributor qualification.

A company may therefore possess a defensible commercial position without holding a strong patent portfolio. The moat is operational. It depends on the cost and time required to qualify a new supplier and secure dependable supply.

What litigation and settlement agreements affect pentobarbital?

Pentobarbital litigation has historically centered more on access, procurement, execution protocols, product liability, and public-records disputes than on patent infringement. Execution-related litigation has challenged drug sourcing, secrecy, importation, state protocols, and constitutional issues. These cases can affect demand indirectly by limiting state access or forcing protocol changes.

No major current settlement structure is known to create broad U.S. exclusivity for standard pentobarbital products. The absence of a patent settlement framework means generic entry is not governed by the type of delayed-entry agreements common in large branded markets.

Is there biosimilar risk for pentobarbital?

No. Pentobarbital is a small-molecule drug, not a biologic. Biosimilar competition under the Public Health Service Act does not apply.

The relevant risk is generic substitution. Because the product is old and chemically defined, competition can arise through abbreviated drug applications or other applicable FDA pathways. The practical challenge is sterile manufacturing and controlled-substance compliance, not biological comparability.

How does pentobarbital compare with competing drugs?

Product category	Relative position versus pentobarbital	Commercial implication
Propofol	More widely used for procedural and general anesthesia	Limits pentobarbital’s hospital anesthesia growth
Midazolam	Common sedative and anticonvulsant alternative	Reduces routine human demand
Phenobarbital	Longer-established anticonvulsant and veterinary product	Competes in seizure and animal-health applications
Thiopental	Similar barbiturate history but limited availability in many markets	Can be a substitute where supplied
Euthanasia-specific veterinary products	Directly competitive in animal-health channels	Product availability and local regulation determine share
Newer anticonvulsants	Better tolerated for many chronic indications	Compresses long-term human clinical use

Pentobarbital retains value where rapid central nervous system depression, established protocols, or veterinary euthanasia use outweigh the safety and monitoring advantages of newer medicines.

What generic launch scenarios exist?

Base case: stable niche supply

One or a few approved suppliers maintain availability. Prices remain above ordinary commodity-generic levels because the market is small and manufacturing is specialized.

Shortage case: temporary price expansion

A plant issue, API interruption, recall, or quota constraint reduces supply. Buyers accept higher prices and may use alternative concentrations or products where legally and clinically appropriate.

Competitive-entry case: price compression

A new approved supplier enters with reliable sterile capacity. Institutional and distributor pricing declines, particularly if the entrant can obtain hospital contracts.

Withdrawal case: market contraction

A principal manufacturer discontinues the product. Remaining suppliers gain pricing power, but demand may migrate to alternative sedatives, anesthetics, or veterinary products.

What is the geographic coverage of the pentobarbital market?

The United States is commercially significant because of its large veterinary market, controlled hospital supply chain, and execution-related demand. European markets have different prescribing rules, euthanasia regulations, procurement practices, and product availability. In some countries, pentobarbital is unavailable or used only under tightly controlled institutional conditions.

Geographic expansion is constrained by:

National narcotics controls.
Import and export permits.
Local marketing authorization.
Veterinary versus human product rules.
Customs scrutiny.
Distribution restrictions.
End-use documentation.

A manufacturer cannot assume that a U.S.-approved product can be sold broadly in Europe, Asia-Pacific, or Latin America without separate regulatory and controlled-substance approvals.

How strong is the pentobarbital patent estate?

The patent estate is weak for the core drug and ordinary injectable products. Commercial defensibility is moderate only where a supplier has an approved product, scarce manufacturing capacity, established distribution, and reliable access to controlled raw materials.

Factor	Assessment
Patent protection	Weak or expired
Regulatory barriers	Moderate
Manufacturing barriers	Moderate to high for sterile injectable supply
Switching costs	Moderate in hospitals and institutional procurement
Generic-entry risk	High over the long term
Supply disruption risk	High
Revenue growth potential	Low
Margin volatility	High

Key Takeaways

Pentobarbital is an off-patent, mature generic drug with no meaningful biosimilar issue.
Public companies do not generally disclose standalone pentobarbital revenue.
The financial trajectory is low-growth, with episodic price increases caused by shortages and supplier concentration.
Human pharmaceutical demand is limited and faces substitution from propofol, midazolam, phenobarbital, and newer anticonvulsants.
Veterinary euthanasia is a more stable commercial segment than routine human use.
Current competitive barriers are primarily sterile manufacturing, controlled-substance compliance, and distribution reliability.
Paragraph IV patent litigation and settlement agreements are not major drivers of current market structure.
A new entrant could obtain regulatory approval without overcoming a strong patent estate, but commercial success would require dependable supply and channel access.
Geographic expansion is limited by national narcotics controls and product-specific marketing authorization.
The principal investment risk is supply disruption, while the principal long-term risk is generic substitution and declining clinical use.

FAQs

Is pentobarbital still commercially available?

Yes, but availability depends on the product presentation, country, manufacturer, and distribution channel. Injectable supply can be intermittent because the market has limited qualified manufacturers.

Does pentobarbital have an active U.S. patent?

The original pentobarbital molecule and legacy products are long off patent. Any current protection would likely involve a narrow formulation, process, container, or method claim rather than the core drug.

Can a generic manufacturer launch pentobarbital without a patent license?

In principle, yes, if the manufacturer satisfies FDA approval requirements and controlled-substance obligations. A patent license may still be necessary if a valid narrow patent covers the specific formulation or process.

Is pentobarbital a controlled substance?

Yes. In the United States, pentobarbital is regulated under the Controlled Substances Act. Manufacturing, distribution, prescribing, storage, and inventory are subject to federal and state controls (DEA, 2023).

What is the largest commercial use of pentobarbital?

The answer varies by geography and product type. Veterinary euthanasia is a recurring commercial use, while human injectable medicine and restricted institutional uses account for smaller, more specialized demand.

References

Drug Enforcement Administration. (2023). Controlled substances alphabetical order. U.S. Department of Justice. https://www.deadiversion.usdoj.gov
U.S. Food and Drug Administration. (2019). Nembutal sodium injection prescribing information. DailyMed. https://dailymed.nlm.nih.gov
U.S. Food and Drug Administration. (2024). Orange Book: Approved drug products with therapeutic equivalence evaluations. https://www.accessdata.fda.gov/scripts/cder/ob/
U.S. Food and Drug Administration. (2024). Drug shortages database. https://www.accessdata.fda.gov/scripts/drugshortages/
U.S. Food and Drug Administration. (2024). Drugs@FDA: FDA-approved drugs. https://www.accessdata.fda.gov/scripts/cder/daf/
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. U.S. Department of Health and Human Services. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book

US Patents:	0
Tradenames:	4
Applicants:	21
NDAs:	28
Drug Master File Entries:	2
Raw Ingredient (Bulk) Api Vendors:	38
Clinical Trials:	9
Drug Prices:	Drug price trends for pentobarbital
DailyMed Link:	pentobarbital at DailyMed

Summary for pentobarbital

Recent Clinical Trials for pentobarbital

Medical Subject Heading (MeSH) Categories for pentobarbital

Anatomical Therapeutic Chemical (ATC) Classes for pentobarbital